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Background
Understanding of the autologous neutralizing antibody
(Nab) targets during HIV-1 infection remains fragmentary
and warrants further investigation in order to be incorpo-
rated during development of a successfully protective vac-
cine. In subtype C infection, the eighteen amino acid
amphipathic alpha2 helix, encoded immediately down-
stream of gp120's V3 domain, undergoes strong positive
selection where mutations track with the neutralization
resistant phenotype; such characteristics would seem to
make the alpha2 helix an attractive potential site for Nab
targeting and escape.
Methods
Utilizing longitudinal samples from subtype C-infected
Zambian patients, we identified autologous Nab escape
variants. In one patient, the alpha2 helix first mutated five
months post-infection. We thus compared a sensitive 0-
month viral envelope against a resistant 5-month viral
envelope to determine whether the alpha2 helix con-
tained direct Nab targets or whether escape variants
depended on alpha2 helix sequence changes to maintain
replicative capacity in vitro.
Results
Residues responsible for conferring neutralization resist-
ance were mapped to two amino acids in the V5 region,
one of which contributed to the CD4 binding site. Alpha2
helix mutations did not alter viral neutralization sensitiv-
ity; these mutations, when introduced in either the pres-
ence or absence of identified V5 escape mutations, failed
to modify in vitro viral replication efficiency.
Conclusion
These studies prompt the acknowledgement that gp120's
alpha2 helix, though positively selected and linked with
escape, does not directly contribute to neutralization
resistance in all patients. Furthermore, if mutation in this
region affects the ability of HIV-1 to replicate, such impact
is subtle enough so as to appear undetectable under in
vitro conditions. Ultimately, the alpha2 helix offers a nota-
ble but incompletely defined contribution to viral
immune evasion.
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